- Home
- PRME vs AQST Comparison
PRME vs AQST Comparison
Compare PRME & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | AQST |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 707.6M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | PRME | AQST |
|---|---|---|
| Price | $3.34 | $3.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $6.42 | ★ $8.83 |
| AVG Volume (30 Days) | 2.4M | ★ 5.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,983,000.00 | ★ $67,430,000.00 |
| Revenue This Year | $95.64 | N/A |
| Revenue Next Year | N/A | $17.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $1.11 | $2.20 |
| 52 Week High | $6.94 | $7.55 |
Technical Indicators
Market Signals| Indicator | PRME | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 48.31 |
| Support Level | $3.16 | $3.61 |
| Resistance Level | $3.39 | $3.99 |
| Average True Range (ATR) | 0.27 | 0.26 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 17.06 | 69.66 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.